Connect with us

Biotech

Predichteon closes €840,000 funding round led by Clave

A spin-off of the Hospital Clínica de Barcelona, the University of Navarra, and the University of San Buenaventura de Cali, the company has so far received funding from the EIT Health Headstart program, the Caixa Impulse program of the La Caixa Foundation, Acció and the health research fund of the Ministry of Health. Predichteon has recently closed a financing round of $1.02 million (€840,000) led by Clave.

Published

on

Predichteon attracts private equity. The Spanish company has closed its first financing round of $1.02 million (€840,000) led by Clave. The company specializes in the development of software solutions for real-time prediction of changes in patient status, as well as clinically relevant adverse events.

The startup will use the funds to complete the regulatory process in Europe and the United States for its first products and to complete the ongoing clinical validation. The transaction was led by the University of Navarra’s R&D&I technology transfer fund, under the management of Clave.

The round has been coordinated by the strategic and corporate finance consulting firm, Inveniam Group, with the participation of international and medical investors. The deal will also help the company pave the regulatory path for further developments and consolidate the workforce with the aim of reaching its first sales in 2022.

Born2Invest’s team of journalists gathers the most interesting business news in a single mobile application. It’s impossible to keep up with everything you’re interested in, but our companion app will help you keep track of the important news. Our app is being updated throughout the day.

Predichteon expects to reach its first sales in 2022

“With the confidence of our investors we will be able to consolidate the project by commercializing the first pack of software solutions and the evolution of new lines of development,” said Pedro Gambús, co-founder and CEO of the company. “Predichteon will contribute to improving clinical practice and patient safety by adding a new dimension to monitoring systems, based on real data and predictive analytics.”

SEE ALSO  Driving efficiency in the modern business: using software to decrease administrative burdens

“We have invested in Predichteon because of the significant value that its products offer for both the patient and the physician,” explained Santiago Lozano, director of the University of Navarra’s R&D&I technology transfer fund. The fund and the venture capital manager currently accumulate a total of fifteen transactions in technology transfer for the healthcare field, with the support of FondICO Global and other investors in the sector.

A spin-off of the Hospital Clínica de Barcelona, the University of Navarra, and the University of San Buenaventura de Cali, the company has so far received funding from the EIT Health Headstart program, the Caixa Impulse program of the La Caixa Foundation, Acció and the health research fund of the Ministry of Health.

__

(Featured image by Pexels via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Suzanne Mitchell juggles the busy life of a full-time mom and entrepreneur while also being a writer-at-large for several business publications. Her work mostly covers the financial sector, including traditional and alternative investing. She shares reports and analyses on the real estate, fintech and cryptocurrency markets. She also likes to write about the health and biotech industry, in particular its intersection with clean water and cannabis. It is one of her goals to always share things of interest to women who want to make their mark in the world.